A Phase 2 interventional study of TERN-601 and Matching Placebo in Overweight or Obesity, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Obesity by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Obesity · Merck & Co., Inc.
Among the 17 studies in Obesity by Merck & Co., Inc, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 2, and was the 17th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →None of the 17 studies in Obesity by Merck & Co., Inc is open now. The open studies under Obesity, anywhere →
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 167 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 497 across the 15 interventional studies. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Obesity by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's enrollment of 167 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
First submitted before Terns, Inc. became part of Merck & Co., Inc.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
(BMI) of:
≥ 30 kg/m\^2 to \< 50 kg/m\^2
OR
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Orally administered once daily.
Drug: TERN-601
Orally administered once daily.
Drug: TERN-601
Orally administered once daily.
Drug: TERN-601
Orally administered once daily.
Drug: TERN-601
Orally administered once daily.
Other: Matching Placebo
Investigational drug
Matching placebo
Percent Change in Body Weight
Percent change (%) in body weight from baseline to Week 12
Time frame: 12 weeks
Change in Body Weight (kg)
Change in body weight (kg) from baseline to Week 12
Time frame: 12 weeks
≥ 5% Weight Loss
Participants achieving ≥ 5% weight loss
Time frame: 12 weeks
| Milestone | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo |
|---|---|---|---|---|---|
| Started | 33 | 34 | 34 | 33 | 33 |
| Completed | 24 | 28 | 28 | 29 | 27 |
| Not completed | 9 | 6 | 6 | 4 | 6 |
| Withdrew: Adverse event | 3 | 0 | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 | 1 | 3 |
| Withdrew: Investigator discretion | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 1 | 1 | 1 |
| Withdrew: Prohibited medication | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other: subject was discontinued due to positive urine drug screen per sponsor guidance | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other: withdrawn from study due to +drug test | 0 | 0 | 1 | 0 | 0 |
Percent change (%) in body weight from baseline to Week 12
| Percent Change (%) | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo |
|---|---|---|---|---|---|
| Percent Change in Body Weight | -2.11 ± 0.688 | -3.85 ± 0.687 | -4.87 ± 0.688 | -3.31 ± 0.688 | -0.30 ± 0.701 |
Change in body weight (kg) from baseline to Week 12
| kg | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo |
|---|---|---|---|---|---|
| Change in Body Weight (kg) | -2.23 ± 0.733 | -4.02 ± 0.735 | -4.97 ± 0.735 | -3.60 ± 0.740 | -0.45 ± 0.746 |
Participants achieving ≥ 5% weight loss
| Participants | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo |
|---|---|---|---|---|---|
| ≥ 5% Weight Loss | 4 (5.2 to 30.8) | 11 (23.8 to 56.5) | 13 (30.1 to 63.4) | 7 (12.4 to 41.9) | 4 (5.4 to 31.8) |
Collected over From enrollment until end of follow-up (Week 16). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TERN-601 250 mg | 0/33 (0%) | 0/33 (0%) | 23/33 (69.7%) |
| TERN-601 500 mg (Slow Titration) | 0/34 (0%) | 0/34 (0%) | 25/34 (73.5%) |
| TERN-601 500 mg | 0/34 (0%) | 1/34 (2.9%) | 27/34 (79.4%) |
| TERN-601 750 mg | 0/33 (0%) | 2/33 (6.1%) | 26/33 (78.8%) |
| Matching Placebo | 0/33 (0%) | 0/33 (0%) | 17/33 (51.5%) |
| Event | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo |
|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/33 | 0/34 | 0/34 | 1/33 | 0/33 |
| Intervertebral disc degenerationMusculoskeletal and connective tissue disorders | 0/33 | 0/34 | 0/34 | 1/33 | 0/33 |
| Drug-induced liver injuryHepatobiliary disorders | 0/33 | 0/34 | 1/34 | 0/33 | 0/33 |
| Event | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 16/33 | 17/34 | 22/34 | 20/33 | 3/33 |
| VomitingGastrointestinal disorders | 2/33 | 10/34 | 13/34 | 11/33 | 0/33 |
| ConstipationGastrointestinal disorders | 2/33 | 2/34 | 8/34 | 4/33 | 1/33 |
| DizzinessNervous system disorders | 1/33 | 3/34 | 7/34 | 2/33 | 0/33 |
| DiarrhoeaGastrointestinal disorders | 4/33 | 4/34 | 4/34 | 1/33 | 2/33 |
| HeadacheNervous system disorders | 4/33 | 0/34 | 3/34 | 2/33 | 1/33 |
| DyspepsiaGastrointestinal disorders | 2/33 | 0/34 | 3/34 | 3/33 | 2/33 |
| EructationGastrointestinal disorders | 3/33 | 0/34 | 3/34 | 0/33 | 0/33 |
| FatigueGeneral disorders | 1/33 | 3/34 | 3/34 | 2/33 | 0/33 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/33 | 0/34 | 2/34 | 2/33 | 1/33 |
| Age, Categorical(Participants) | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 28 | 31 | 29 | 29 | 29 | 146 |
| >=65 years | 5 | 3 | 5 | 4 | 4 | 21 |
| Age, Continuous(Years) | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 47.6 ± 15.87 | 48.1 ± 13.33 | 53.6 ± 11.43 | 50.5 ± 13.82 | 51.2 ± 12.93 | 50.2 ± 13.56 |
| Sex: Female, Male(Participants) | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 26 | 27 | 27 | 26 | 26 | 132 |
| Male | 7 | 7 | 7 | 7 | 7 | 35 |
| Race (NIH/OMB)(Participants) | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 0 | 0 | 0 | 3 |
| Asian | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 10 | 10 | 8 | 38 |
| White | 26 | 26 | 23 | 22 | 24 | 121 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 1 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 7 | 11 | 9 | 11 | 47 |
| Not Hispanic or Latino | 24 | 27 | 23 | 24 | 22 | 120 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Weight (kg)(kg) | TERN-601 250 mg | TERN-601 500 mg (Slow Titration) | TERN-601 500 mg | TERN-601 750 mg | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 99.63 ± 18.643 | 99.46 ± 16.690 | 100.22 ± 16.702 | 101.84 ± 18.359 | 99.68 ± 20.768 | 101.16 ± 18.075 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2025 to primary completion in Aug 2025, 5 months.
Results were first posted in Aug 2026, 11 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 5 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →